Get Ready to Snap Up the Latest Financial Scoop: Snap One Holdings Corp. to Unveil Fiscal Second Quarter 2022 Results on August 11th at 4:30 PM ET!

Welcome to the Future of Smart Living with Snap One Join Snap One Holdings Corp.’s Financial Results Conference Call on August 11, 2022 CHARLOTTE, N.C., July 26, 2022 (GLOBE NEWSWIRE) — Snap One Holdings Corp. (Nasdaq: SNPO) (“Snap One” or the “Company”), a provider of smart living products, services and software to professional integrators, will…

Read More

Uncovering the Truth: Pomerantz Law Firm Investigates Claims Against Charles Schwab Corporation on Behalf of Investors

Investigation into The Charles Schwab Corporation New York, July 26, 2022 (GLOBE NEWSWIRE) – Pomerantz Law Firm Investigating Claims on Behalf of Investors Pomerantz LLP, a well-known law firm based in New York, is currently conducting an investigation on behalf of investors of The Charles Schwab Corporation (NYSE: SCHW). Investors who have purchased shares of…

Read More

Federal Reserve’s Upcoming Meeting: Powell to Consider Economic Slowdown, But Will Still Push for Higher Interest Rates – A Preview

The Potential Impact of the FOMC Statement and Powell’s Press Conference The FOMC Statement and Powell’s Press Conference The Federal Open Market Committee (FOMC) is set to release its statement at 1800 GMT on Wednesday, 27 July 2022. Following this, Federal Reserve Chair Powell will hold a press conference at 1830 GMT. Market analysts and…

Read More

Breaking News: Inotiv Inc. Expands Genetic Toxicology Services with GLP Assays at Rockville, MD Location!

Inotiv, Inc. Continues to Expand Genetic Toxicology Offering with Support of GLP Assays at Rockville Exciting News from Inotiv, Inc. WEST LAFAYETTE, Ind., July 26, 2022 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) Attention all science enthusiasts and industry professionals, we have some exciting news to share! Inotiv, Inc., a leading contract research organization specializing…

Read More

Get Ready for Exciting News: Medicinova Launches Phase 2 Trial for MN-001 Tipelukast in NAFLD with Type 2 Diabetes and Hypertriglyceridemia!

Welcome to the MediciNova Phase 2 Trial Blog! Celebrating New Breakthroughs in Medical Research July 26, 2022 Hey there, readers! Have you heard the latest news from MediciNova, Inc.? They just announced the initiation of a Phase 2 clinical trial to evaluate MN-001 (tipelukast) for the treatment of patients with non-alcoholic fatty liver disease (NAFLD)…

Read More